188 related articles for article (PubMed ID: 27624917)
1. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic review.
Okuno M; Hatano E; Nishino H; Seo S; Taura K; Uemoto S
Eur J Surg Oncol; 2017 Jun; 43(6):1003-1012. PubMed ID: 27624917
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis.
Wang L; Sun Y; Zhao B; Zhang H; Yu Q; Yuan X
Oncotarget; 2016 Aug; 7(34):55732-55740. PubMed ID: 27248177
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents.
García-Alfonso P; Ferrer A; Gil S; Dueñas R; Pérez MT; Molina R; Capdevila J; Safont MJ; Castañón C; Cano JM; Lara R
Target Oncol; 2015 Dec; 10(4):453-65. PubMed ID: 25752908
[TBL] [Abstract][Full Text] [Related]
4. Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis.
Bogach J; Levine O; Parpia S; Valencia M; Ruo L; Serrano P
J Gastrointest Surg; 2018 Mar; 22(3):523-528. PubMed ID: 29204907
[TBL] [Abstract][Full Text] [Related]
5. Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis.
Sugiyama M; Uehara H; Shin Y; Shiokawa K; Fujimoto Y; Mano Y; Komoda M; Nakashima Y; Sugimachi K; Yamamoto M; Morita M; Toh Y
Surg Today; 2022 Apr; 52(4):633-642. PubMed ID: 34762175
[TBL] [Abstract][Full Text] [Related]
6. Is Surgical Treatment Effective or Contraindicated in Patients with Colorectal Cancer Liver Metastases Exhibiting Extrahepatic Metastasis?
Hirokawa F; Komeda K; Asakuma M; Shimizu T; Kagota S; Tomioka A; Uchiyama K
J Gastrointest Surg; 2022 Mar; 26(3):594-601. PubMed ID: 34506021
[TBL] [Abstract][Full Text] [Related]
7. Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis: A Retrospective Cohort Study.
Chen Y; Zhu D; Chen M; Xu Y; Ye Q; Wang X; Xu P; Feng Q; Ji M; Wei Y; Fan J; Xu J
Clin Colorectal Cancer; 2023 Dec; 22(4):464-473.e5. PubMed ID: 37730473
[TBL] [Abstract][Full Text] [Related]
8. The High Incidence of Occult Carcinoma in Total Hepatectomy Specimens of Patients Treated for Unresectable Colorectal Liver Metastases With Liver Transplant.
Chávez-Villa M; Ruffolo LI; Al-Judaibi BM; Fujiki M; Hashimoto K; Kallas J; Kwon CHD; Nair A; Orloff MS; Pineda-Solis K; Raj R; Sasaki K; Tomiyama K; Aucejo F; Hernandez-Alejandro R
Ann Surg; 2023 Nov; 278(5):e1026-e1034. PubMed ID: 36692112
[TBL] [Abstract][Full Text] [Related]
9. A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer.
Lebeck Lee CM; Ziogas IA; Agarwal R; Alexopoulos SP; Ciombor KK; Matsuoka LK; Brown DB; Eng C
Cancer; 2022 Jun; 128(12):2243-2257. PubMed ID: 35285949
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first-line systemic treatment.
He J; Li W; Zhou J; Sun H; Zhou C; Liu Y; Quan T; Fan W; Pan Z; Lin J; Peng J
Eur J Radiol; 2023 Aug; 165():110950. PubMed ID: 37437437
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of pre-treatment dynamic contrast-enhanced ultrasound for assessing the response of colorectal liver metastases to chemotherapy plus targeted therapy: a dual-institutional study.
Zhou BY; Liu H; Pu YY; Wang LF; Sun YK; Yin HH; Lu D; Ye X; Hu XY; Wang X; Han H; Xia HS; Zhao CK; Xu HX
Abdom Radiol (NY); 2024 Feb; 49(2):414-424. PubMed ID: 37853236
[TBL] [Abstract][Full Text] [Related]
12. Assessing the effectiveness of targeted agents in adjuvant therapy for patients with metastatic colorectal cancer undergoing surgical resection: a retrospective cohort study.
Su YC; Wu CC; Chen YH; Su CC; Chang YC; Hsieh MC; Kao Yang YH
Ther Adv Med Oncol; 2024; 16():17588359241246427. PubMed ID: 38655393
[TBL] [Abstract][Full Text] [Related]
13. Update to 'A Contemporary Systematic Review on Liver Transplantation for Unresectable Liver Metastasis of Colorectal Cancer'.
Wehrle CJ; Fujiki M; Schlegel A; Whitsett Linganna M; Pita A; Kim JK; Kwon DCH; Miller C; Hashimoto K; Dueland S; Sasaki K; Sapisochin G; Line PD; Hernandez-Alejandro R; Aucejo F
Ann Surg Oncol; 2024 Feb; 31(2):697-700. PubMed ID: 37996635
[TBL] [Abstract][Full Text] [Related]
14. Colorectal liver metastases: Correlations of contrast-enhanced ultrasound features with tumor clinicopathological factors and clinical outcomes following conversion therapy.
Zhang XL; Wang HT; Tang Y; Lu Q; Yuan HX; Wang X; Liu LH; Zhu DX; Wang WP
Clin Hemorheol Microcirc; 2024; 86(3):339-356. PubMed ID: 37927253
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in treatment for colorectal liver metastasis.
Oki E; Ando K; Nakanishi R; Sugiyama M; Nakashima Y; Kubo N; Kudou K; Saeki H; Nozoe T; Emi Y; Maehara Y
Ann Gastroenterol Surg; 2018 May; 2(3):167-175. PubMed ID: 29863162
[TBL] [Abstract][Full Text] [Related]
16. Estimating Efficacy of Conversion Therapy on Patients with Initially Unresectable Colorectal Cancer Liver Metastases by using MRI: Development of a Predictive Score.
Liu J; Tang W; Ye L; Miao G; Zeng M; Liu L
Acad Radiol; 2024 May; ():. PubMed ID: 38734578
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic agents in metastatic colorectal cancer.
Konda B; Shum H; Rajdev L
World J Gastrointest Oncol; 2015 Jul; 7(7):71-86. PubMed ID: 26191351
[TBL] [Abstract][Full Text] [Related]
18. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M; Kanda M; Ishigure K; Matsuoka H; Sato Y; Takahashi T; Tanaka C; Deguchi T; Shibata Y; Sato M; Inagaki H; Matsui T; Kondo A; Takano N; Tanaka H; Sakamoto J; Oba K; Kondo K
Ann Surg Oncol; 2017 Feb; 24(2):546-553. PubMed ID: 27638675
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Kerr RS; Love S; Segelov E; Johnstone E; Falcon B; Hewett P; Weaver A; Church D; Scudder C; Pearson S; Julier P; Pezzella F; Tomlinson I; Domingo E; Kerr DJ
Lancet Oncol; 2016 Nov; 17(11):1543-1557. PubMed ID: 27660192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
